Phase 4
Completed N=239
A Clinical Trial of Two Periarticular Multimodal Drug Injections in Total Hip and Knee Arthroplasty
Total Hip and Knee Arthroplasty
Source: ClinicalTrials.gov NCT02543801 ↗
Enrolled (actual)
239
Serious AEs
0.0%
Results posted
Oct 2019
Primary outcomePrimary: Pain Score — 3.78; 3.85; 3.3; 3.4 score on a scale
Summary
This study evaluates two routinely used drug combinations for periarticular injection following total hip and knee arthroplasty for pain control. One group will receive liposomal bupivacaine, bupivacaine, clonidine, epinephrine and ketorolac. The other group will receive ropivacaine, clonidine, epinephrine and ketorolac.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pain Score |
3.78; 3.85; 3.3; 3.4 | — |
| SECONDARY Narcotic Consumption |
48.8; 57.4; 52.2; 50.0 | — |
| SECONDARY Length of Stay |
33.8; 50.3; 36.0; 38.4 | — |
Eligibility Criteria
Inclusion Criteria
- Hip Arthritis (osteoarthritis, post traumatic, inflammatory, and avascular necrosis)
Exclusion Criteria
- Current use of opioid drugs
- Revision surgery
- Surgical complication (femoral fracture with implant insertion)
- Inability to provide Informed Consent
Data sourced from ClinicalTrials.gov (NCT02543801). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.